Mauritania
Tuberculosis profile
Population  2013 3.9 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1 (0.54–1.5) 26 (14–40)
Mortality (HIV+TB only) 0.035 (<0.01–0.15) 0.9 (0.01–3.9)
Prevalence  (includes HIV+TB) 7.9 (3.9–13) 203 (100–341)
Incidence  (includes HIV+TB) 4.5 (3.2–6.1) 115 (82–157)
Incidence (HIV+TB only) 0.09 (0–0.44) 2.3 (0–11)
Case detection, all forms (%) 50 (37–69)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 1.9 (0.1–5.3) 20 (0.1–40)
MDR-TB cases among notified pulmonary
TB cases
30 (2–84) 22 (0–43)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 1 303   108
Pulmonary, clinically diagnosed 288   0
Extrapulmonary 524   0
       
Total new and relapse 2 223    
Previously treated, excluding relapses 0    
Total cases notified 2 223    
Among 2 368 new cases:
65 (3%) cases aged under 15 years; male:female ratio: 2.1
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB      
Laboratory-confirmed RR-/MDR-TB cases     0
Patients started on MDR-TB treatment      
TB/HIV 2013 Number (%)
TB patients with known HIV status 0 (0)
HIV-positive TB patients 0  
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 0  
HIV-positive TB patients on antiretroviral therapy (ART) 0  
HIV-positive people screened for TB    
HIV-positive people provided with IPT 0  
Treatment success rate (%)
New and relapse cases registered in 2012 68
Previously treated cases, excluding relapse, registered in 2012 71
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011  
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population)  
Culture (per 5 million population)  
Drug susceptibility testing (per 5 million population)  
Sites performing Xpert MTB/RIF  
Is second-line drug susceptibility testing available?  
Financing TB control 2014  
National TB programme budget (US$ millions)  
% Funded domestically  
% Funded internationally  
% Unfunded  
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-09-04 Data: www.who.int/tb/data